<DOC>
	<DOCNO>NCT00178464</DOCNO>
	<brief_summary>Neurologic complication secondary cerebrovascular damage prevalent child sickle cell disease . These patient experience clinically overt cerebrovascular accident `` silent infarction '' demonstrate magnetic resonance imaging ( MRI ) . They also risk neurocognitive abnormalities.We hypothesize daily , low-dose aspirin therapy safely diminish incidence progression cognitive deficit well predisposition overt silent stroke child homozygous sickle cell disease ( Hgb SS ) hemoglobin S Beta Zero Thalassemia ( Hgb SB-0 Thal ) . In order optimize design future trial test hypothesis , propose pilot study test safety tolerability aspirin young child sickle cell disease .</brief_summary>
	<brief_title>Aspirin Prophylaxis Sickle Cell Disease</brief_title>
	<detailed_description>The trial 's primary objective evaluate safety tolerability daily low-dose aspirin child sickle cell disease . The secondary objective assess ( 1 ) The feasibility recruit child Hgb SS Hgb S Beta-0 Thalassemia aspirin trial , ( 2 ) The level compliance aspirin administration propose patient population , ( 3 ) The useful assessment battery age-appropriate neurocognitive test , ( 4 ) The feasibility magnetic resonance imaging ( MRI ) magnetic resonance angiography ( MRA ) study utility classification system use group comparison , ( 5 ) Preliminary data regard trend transcranial Doppler ( TCD ) ultrasound velocity time validity use trend group comparison , ( 6 ) Preliminary data regard effect aspirin therapy incidence cognitive deficit , image change , overt stroke , painful crisis , acute chest syndrome . Subjects include child age 2 7.99 year document Hgb SS Hgb S Beta-0 Thalassemia follow Golisano Children 's Hospital Strong University Miami . All subject receive daily aspirin ( 2.5 - 5.1 mg/kg daily ) . Subjects receive therapy 12 month . There careful laboratory clinical monitoring every 3-6 month frequently need . Pre post treatment clinical complication , neurocognitive testing , MRI , MRA , TCD study assess .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>1 . Children age 2 7.99 year diagnosis Hb SS Hb SÃŸ0 thalassemia , document hemoglobin electrophoresis complete blood count ( CBC ) . 2 . Influenza vaccination previous year intend upcoming flu season . 3 . Evidence past infection , immunization , varicella . 4 . Negative pregnancy test girls childbearing potential . 5 . Informed consent sign parent legal guardian . 1 . Prior history overt stroke cerebral hemorrhage . 2 . Known history allergic reaction aspirin . 3 . History Reye 's syndrome 4 . Diagnosis G6PD deficiency von Willebrand 's disease 5 . Prolongation bleed time abnormal closure time , prothrombin time ( PT ) , partial thromboplastin time ( PTT ) . 6 . Active gastrointestinal ( GI ) bleed history GI bleeding . 7 . Hepatic disease ( AST ALT &gt; 2x upper limit normal , Direct bilirubin &gt; 1.5 mg/dL ) renal disease ( creatinine &gt; 2x upper limit normal 2 mg/dl , whichever small ) . The exclusion criterion laboratory study range specify great 2 time upper limit normal . 8 . Hypertension ( BP &gt; 95 % age height ) . 9 . Current treatment chronic transfusion therapy . 10 . Evidence hemorrhage MRI . 11 . A mean TCD velocity &gt; 200 cm/sec . middle cerebral artery ( MCA ) internal carotid artery ( ICA ) . 12 . Evidence Moyamoya syndrome MRA . 13 . Evidence pregnancy . 14 . Evidence inability comply test procedure . 15 . Inability provide inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>7 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>sickle cell disease</keyword>
	<keyword>hemoglobin SS disease</keyword>
	<keyword>hemoglobin S Beta-0 Thalassemia</keyword>
	<keyword>silent infarction sickle cell disease</keyword>
	<keyword>overt stroke sickle cell disease</keyword>
	<keyword>aspirin</keyword>
	<keyword>transcranial Doppler ultrasound</keyword>
	<keyword>neurocognitive testing</keyword>
</DOC>